



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	Journal of Advances in Medical and Pharmaceutical Sciences
Manuscript Number:	2014_JAMPS_12865
Title of the Manuscript:	Is Cystoid Macular Edema More Frequent In Vitrectomized Internal Limiting Membrane-peeled Eyes Undergoing Phacoemulsification?
Type of the Article	Short communication

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
There is still issues with this manuscript: Line 20-21: "CME occurred in 38% of group 4 compared to 0% of group 1, 11% of group 2 and 11% of group 3." Why was group 4 chosen first? For ease of reading, it should be stated plainly in percentages for group 1, 2, 3 and 4. If comparison would to be used, the CME rate should be compared with the control group (group 1). Line 23-26: it should be stated that the mean logMAR BCVA is for the 6 patients with CME. As with my previous comments, I feel this information adds no value to the paper. It would make more sense to me if you gave mean BCVA and CMT of each subgroup (obviously excluding group 1 since there is no CME patients). Then you are saying that CME not only occurred more frequently with group 4 but perhaps the BCVA and CMT were worse as well (or whatever the finding is). Line 28-30: There is no mention of recurrence rate in the result section of the abstract. How then can you make that conclusion? Line 177: Late recurrence: The number of cases who developed acute (???) postoperative CME Line 201: 61-year-old	We agree with the Final Evaluator and have changed the manuscript accordingly Line 20-21 CME was noted in 6/43 patients (14%). CME occurred in 0% of group 1, 11% of group 2, 11% of group 3 and 38% of group 4. We agree with the Final Evaluator that this information adds little to the overall paper, we were asked by previous reviewers to include this data. We have included the separated data in figures 3 A and B. There were no significant differences between the groups. We have chosen to give the overall figures for the abstract, as the subgroups would be too much for the abstract. Line 23-26 The mean ($\pm$ standard deviation) LogMAR best-corrected mean visual acuity (BCVA) for CME patients improved from 0.44 ($\pm$ 0.27) at time of CME diagnosis to 0.35 ($\pm$ 0.19), with a mean decrease in CMT from 392.2 ($\pm$ 102.5) μm to 287.7 ($\pm$ 34.0) μm. Line 28: Recurrence rate deleted Line 177 Acute deleted